Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

913 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, Marcus R, Kimby E, Herold M, Sebban C, Gyan E, Foon K, Nielsen T, Vitolo U, Salles GA, Shi Q, Flowers CR. Casulo C, et al. Among authors: hiddemann w. Blood. 2022 Mar 17;139(11):1684-1693. doi: 10.1182/blood.2020010263. Blood. 2022. PMID: 34614146 Free PMC article.
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. Shi Q, et al. Among authors: hiddemann w. J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029309
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
Casulo C, Dixon JG, Ou FS, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus R, Kimby E, Herold M, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Shi Q, Flowers CR. Casulo C, et al. Among authors: hiddemann w. Blood Adv. 2021 Mar 23;5(6):1737-1745. doi: 10.1182/bloodadvances.2020002724. Blood Adv. 2021. PMID: 33749762 Free PMC article.
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Dreyling M, et al. Among authors: hiddemann w. Blood. 2005 Apr 1;105(7):2677-84. doi: 10.1182/blood-2004-10-3883. Epub 2004 Dec 9. Blood. 2005. PMID: 15591112 Free article. Clinical Trial.
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. Buske C, et al. Among authors: hiddemann w. Blood. 2006 Sep 1;108(5):1504-8. doi: 10.1182/blood-2006-01-013367. Epub 2006 May 11. Blood. 2006. PMID: 16690968 Free article. Clinical Trial.
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. Hoster E, et al. Among authors: hiddemann w. Blood. 2008 Jan 15;111(2):558-65. doi: 10.1182/blood-2007-06-095331. Epub 2007 Oct 25. Blood. 2008. PMID: 17962512 Free article.
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R. Mottok A, et al. Among authors: hiddemann w. Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9. Blood. 2018. PMID: 29122756 Free PMC article. Clinical Trial.
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.
Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E, Weigert O. Jurinovic V, et al. Among authors: hiddemann w. Biol Blood Marrow Transplant. 2018 Jun;24(6):1172-1179. doi: 10.1016/j.bbmt.2018.03.022. Epub 2018 Mar 29. Biol Blood Marrow Transplant. 2018. PMID: 29605716 Free article. Clinical Trial.
Impact of age on clinical risk scores in follicular lymphoma.
Alig S, Jurinovic V, Pastore A, Haebe S, Schmidt C, Zoellner AK, Dreyling M, Unterhalt M, Hoster E, Hiddemann W, Weigert O. Alig S, et al. Among authors: hiddemann w. Blood Adv. 2019 Apr 9;3(7):1033-1038. doi: 10.1182/bloodadvances.2019032136. Blood Adv. 2019. PMID: 30940638 Free PMC article.
913 results